Perspective Therapeutics wins EU orphan drug status for [212Pb]VMT-α-NET in GEP-NETs
CATX•EU orphan designation granted for lead candidate
European Commission granted orphan medicinal product designation for Perspective Therapeutics’ [212Pb]VMT-α-NET in gastroenteropancreatic neuroendocrine tumors.
The decision followed a positive opinion from the EMA’s Committee for Orphan Medicinal Products.
Potential development and commercialization benefits
The status may offer EU development incentives, including fee reductions, protocol support, and up to 10 years of market exclusivity if approved.
